CA3224546A1 - Utilisation du migalastat dans le traitement des patients atteints de lamaladie de fabry presentant une deficience renale - Google Patents
Utilisation du migalastat dans le traitement des patients atteints de lamaladie de fabry presentant une deficience renale Download PDFInfo
- Publication number
- CA3224546A1 CA3224546A1 CA3224546A CA3224546A CA3224546A1 CA 3224546 A1 CA3224546 A1 CA 3224546A1 CA 3224546 A CA3224546 A CA 3224546A CA 3224546 A CA3224546 A CA 3224546A CA 3224546 A1 CA3224546 A1 CA 3224546A1
- Authority
- CA
- Canada
- Prior art keywords
- migalastat
- patient
- administration
- salt
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LXBIFEVIBLOUGU-DPYQTVNSSA-N migalastat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O LXBIFEVIBLOUGU-DPYQTVNSSA-N 0.000 title claims abstract description 329
- 229950007469 migalastat Drugs 0.000 title claims abstract description 324
- 206010062237 Renal impairment Diseases 0.000 title claims abstract description 166
- 238000011282 treatment Methods 0.000 title abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 139
- 230000003907 kidney function Effects 0.000 claims abstract description 81
- 208000024720 Fabry Disease Diseases 0.000 claims abstract description 58
- 201000001474 proteinuria Diseases 0.000 claims abstract description 52
- 239000012458 free base Substances 0.000 claims abstract description 22
- 230000008859 change Effects 0.000 claims description 79
- 238000002641 enzyme replacement therapy Methods 0.000 claims description 71
- 230000035772 mutation Effects 0.000 claims description 45
- 230000000977 initiatory effect Effects 0.000 claims description 31
- ZJIHMALTJRDNQI-OLALXQGDSA-N (2r,3s,4r,5s)-2-(hydroxymethyl)piperidine-3,4,5-triol;hydrochloride Chemical compound Cl.OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O ZJIHMALTJRDNQI-OLALXQGDSA-N 0.000 claims description 28
- 229950010505 migalastat hydrochloride Drugs 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 19
- 238000003556 assay Methods 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 12
- 108060006698 EGF receptor Proteins 0.000 claims 6
- 239000007909 solid dosage form Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 44
- 238000000034 method Methods 0.000 abstract description 39
- 230000001965 increasing effect Effects 0.000 abstract description 29
- 230000006641 stabilisation Effects 0.000 abstract description 4
- 238000011105 stabilization Methods 0.000 abstract description 4
- 230000002861 ventricular Effects 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 description 66
- 102000004190 Enzymes Human genes 0.000 description 59
- 108090000790 Enzymes Proteins 0.000 description 59
- 102000004169 proteins and genes Human genes 0.000 description 58
- 238000002560 therapeutic procedure Methods 0.000 description 58
- 229940088598 enzyme Drugs 0.000 description 56
- 108010006519 Molecular Chaperones Proteins 0.000 description 36
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 28
- 230000000144 pharmacologic effect Effects 0.000 description 25
- 230000007423 decrease Effects 0.000 description 24
- 210000003734 kidney Anatomy 0.000 description 19
- GRGNVOCPFLXGDQ-TWHXEDJUSA-N (2r,3r,4s,5r,6r)-2-[(2r,3r,4r,5r,6s)-6-[(2r,3s,4r,5r,6r)-6-[(e,2s,3r)-2-amino-3-hydroxyoctadec-4-enoxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](N)[C@H](O)/C=C/CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 GRGNVOCPFLXGDQ-TWHXEDJUSA-N 0.000 description 18
- 239000000758 substrate Substances 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 229940109239 creatinine Drugs 0.000 description 15
- 239000006186 oral dosage form Substances 0.000 description 15
- 102100038451 CDK5 regulatory subunit-associated protein 2 Human genes 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 13
- 210000000265 leukocyte Anatomy 0.000 description 13
- 230000035508 accumulation Effects 0.000 description 12
- 238000009825 accumulation Methods 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- 210000003712 lysosome Anatomy 0.000 description 12
- 230000001868 lysosomic effect Effects 0.000 description 12
- 230000006872 improvement Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- 230000006735 deficit Effects 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 230000032258 transport Effects 0.000 description 9
- 102000005431 Molecular Chaperones Human genes 0.000 description 8
- 208000001647 Renal Insufficiency Diseases 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000008030 elimination Effects 0.000 description 8
- 238000003379 elimination reaction Methods 0.000 description 8
- 201000006370 kidney failure Diseases 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102220076744 rs796052639 Human genes 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 208000020832 chronic kidney disease Diseases 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 150000002339 glycosphingolipids Chemical class 0.000 description 7
- 230000000750 progressive effect Effects 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 230000001771 impaired effect Effects 0.000 description 6
- 230000002132 lysosomal effect Effects 0.000 description 6
- 102220045124 rs587781846 Human genes 0.000 description 6
- 238000004088 simulation Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000024924 glomerular filtration Effects 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 208000017169 kidney disease Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 102200023312 rs121912940 Human genes 0.000 description 5
- 102200131211 rs267607647 Human genes 0.000 description 5
- 102200076442 rs28935197 Human genes 0.000 description 5
- 102220103395 rs765325777 Human genes 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 230000000087 stabilizing effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- 101000718525 Homo sapiens Alpha-galactosidase A Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 102200076455 c.254G>A Human genes 0.000 description 4
- 102220364489 c.620A>C Human genes 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 238000005094 computer simulation Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000004750 isotope dilution mass spectroscopy Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 102220197685 rs1060339 Human genes 0.000 description 4
- 102220282248 rs1555570250 Human genes 0.000 description 4
- 102220283879 rs1555738868 Human genes 0.000 description 4
- 102200012125 rs367543257 Human genes 0.000 description 4
- 102220028760 rs398123226 Human genes 0.000 description 4
- 102220030657 rs398124205 Human genes 0.000 description 4
- 102220088308 rs749827433 Human genes 0.000 description 4
- 102220093869 rs776719541 Human genes 0.000 description 4
- 102220072783 rs794729227 Human genes 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 102100026277 Alpha-galactosidase A Human genes 0.000 description 3
- 102220481461 Alpha-galactosidase A_D313Y_mutation Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101150014526 Gla gene Proteins 0.000 description 3
- 210000001766 X chromosome Anatomy 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 102220363251 c.216G>A Human genes 0.000 description 3
- 102220418143 c.687T>A Human genes 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- -1 i.e. Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 238000013105 post hoc analysis Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 102200047112 rs104894008 Human genes 0.000 description 3
- 102220100485 rs147078770 Human genes 0.000 description 3
- 102220087828 rs375538532 Human genes 0.000 description 3
- 102200076596 rs397515874 Human genes 0.000 description 3
- 102220200219 rs770497192 Human genes 0.000 description 3
- 102200076503 rs782197638 Human genes 0.000 description 3
- 102200076871 rs797044613 Human genes 0.000 description 3
- 102220082942 rs863223870 Human genes 0.000 description 3
- 102220094763 rs876658184 Human genes 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
- 208000006029 Cardiomegaly Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 230000006782 ER associated degradation Effects 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 208000015439 Lysosomal storage disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 108010049936 agalsidase alfa Proteins 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 102220364330 c.1066C>G Human genes 0.000 description 2
- 102200076867 c.124A>G Human genes 0.000 description 2
- 102220350264 c.175G>A Human genes 0.000 description 2
- 102200006386 c.179C>T Human genes 0.000 description 2
- 102200076464 c.272T>C Human genes 0.000 description 2
- 102200076470 c.290C>T Human genes 0.000 description 2
- 102220419285 c.383G>A Human genes 0.000 description 2
- 102200076353 c.404C>T Human genes 0.000 description 2
- 102220362294 c.408T>A Human genes 0.000 description 2
- 102220417856 c.408T>G Human genes 0.000 description 2
- 102220411681 c.497T>G Human genes 0.000 description 2
- 102220362048 c.525C>G Human genes 0.000 description 2
- 102200006355 c.58G>C Human genes 0.000 description 2
- 102220432152 c.596T>G Human genes 0.000 description 2
- 102200106570 c.662A>C Human genes 0.000 description 2
- 102220365499 c.750G>C Human genes 0.000 description 2
- 102220345148 c.800T>C Human genes 0.000 description 2
- 102220362135 c.812G>A Human genes 0.000 description 2
- 102200104863 c.840A>C Human genes 0.000 description 2
- 102220407771 c.870G>C Human genes 0.000 description 2
- 102220407770 c.887T>C Human genes 0.000 description 2
- 102200077291 c.893A>G Human genes 0.000 description 2
- 102220424908 c.897C>A Human genes 0.000 description 2
- 102220402990 c.925G>C Human genes 0.000 description 2
- 102220357611 c.931C>G Human genes 0.000 description 2
- 102220346920 c.935A>G Human genes 0.000 description 2
- 102220400287 c.955A>T Human genes 0.000 description 2
- 210000001736 capillary Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 230000019975 dosage compensation by inactivation of X chromosome Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 230000007331 pathological accumulation Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 210000000557 podocyte Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 102220274033 rs1023059961 Human genes 0.000 description 2
- 102200038750 rs104894255 Human genes 0.000 description 2
- 102200077151 rs104894827 Human genes 0.000 description 2
- 102200077295 rs104894828 Human genes 0.000 description 2
- 102200077287 rs104894830 Human genes 0.000 description 2
- 102200076859 rs104894835 Human genes 0.000 description 2
- 102200076370 rs104894837 Human genes 0.000 description 2
- 102200076364 rs104894845 Human genes 0.000 description 2
- 102200077288 rs104894846 Human genes 0.000 description 2
- 102200077213 rs104894852 Human genes 0.000 description 2
- 102220197724 rs1057519664 Human genes 0.000 description 2
- 102200103784 rs1057519986 Human genes 0.000 description 2
- 102220217549 rs1060500666 Human genes 0.000 description 2
- 102220218947 rs1060500755 Human genes 0.000 description 2
- 102200106056 rs1060501209 Human genes 0.000 description 2
- 102220222822 rs1060501231 Human genes 0.000 description 2
- 102220219760 rs1060501259 Human genes 0.000 description 2
- 102220223535 rs1060501767 Human genes 0.000 description 2
- 102220222913 rs1060502603 Human genes 0.000 description 2
- 102220223293 rs1060502955 Human genes 0.000 description 2
- 102220214386 rs1060504418 Human genes 0.000 description 2
- 102220230045 rs1064795269 Human genes 0.000 description 2
- 102200012177 rs111033775 Human genes 0.000 description 2
- 102200077177 rs111422676 Human genes 0.000 description 2
- 102220236198 rs1131691936 Human genes 0.000 description 2
- 102220036895 rs115031549 Human genes 0.000 description 2
- 102220288988 rs118192217 Human genes 0.000 description 2
- 102200128188 rs121908803 Human genes 0.000 description 2
- 102200119742 rs121917865 Human genes 0.000 description 2
- 102220004336 rs121964873 Human genes 0.000 description 2
- 102200104802 rs13406336 Human genes 0.000 description 2
- 102220276769 rs1354702896 Human genes 0.000 description 2
- 102220272546 rs1391505912 Human genes 0.000 description 2
- 102220125906 rs139690694 Human genes 0.000 description 2
- 102220293205 rs143053635 Human genes 0.000 description 2
- 102220060061 rs143198946 Human genes 0.000 description 2
- 102220306916 rs144060196 Human genes 0.000 description 2
- 102220075238 rs144565191 Human genes 0.000 description 2
- 102220282140 rs146777134 Human genes 0.000 description 2
- 102220286117 rs1477257356 Human genes 0.000 description 2
- 102220012150 rs148158093 Human genes 0.000 description 2
- 102220095159 rs148517156 Human genes 0.000 description 2
- 102220054879 rs149391489 Human genes 0.000 description 2
- 102220027344 rs151244108 Human genes 0.000 description 2
- 102220276581 rs1553127574 Human genes 0.000 description 2
- 102220276595 rs1553131446 Human genes 0.000 description 2
- 102220316067 rs1553348822 Human genes 0.000 description 2
- 102200027501 rs1553350676 Human genes 0.000 description 2
- 102220276999 rs1553350772 Human genes 0.000 description 2
- 102220288652 rs1553507249 Human genes 0.000 description 2
- 102220260525 rs1554097567 Human genes 0.000 description 2
- 102220320409 rs1554303953 Human genes 0.000 description 2
- 102220320593 rs1554306309 Human genes 0.000 description 2
- 102220278792 rs1554559273 Human genes 0.000 description 2
- 102220311388 rs1554963305 Human genes 0.000 description 2
- 102220266514 rs1555165534 Human genes 0.000 description 2
- 102220325152 rs1555338762 Human genes 0.000 description 2
- 102220281560 rs1555461584 Human genes 0.000 description 2
- 102220288519 rs1555475519 Human genes 0.000 description 2
- 102220281751 rs1555608765 Human genes 0.000 description 2
- 102220283530 rs1555609260 Human genes 0.000 description 2
- 102220283878 rs1555738411 Human genes 0.000 description 2
- 102220283177 rs1555755289 Human genes 0.000 description 2
- 102220283775 rs1555926890 Human genes 0.000 description 2
- 102220295376 rs1555927942 Human genes 0.000 description 2
- 102200152947 rs1555937244 Human genes 0.000 description 2
- 102220275902 rs1555986305 Human genes 0.000 description 2
- 102220291916 rs1555987150 Human genes 0.000 description 2
- 102220027111 rs1799977 Human genes 0.000 description 2
- 102220061701 rs181695922 Human genes 0.000 description 2
- 102220308779 rs186183947 Human genes 0.000 description 2
- 102200077342 rs190347120 Human genes 0.000 description 2
- 102220008873 rs193921400 Human genes 0.000 description 2
- 102220034911 rs199475589 Human genes 0.000 description 2
- 102220034865 rs199475626 Human genes 0.000 description 2
- 102220025220 rs199476357 Human genes 0.000 description 2
- 102220244117 rs200243989 Human genes 0.000 description 2
- 102220289530 rs201201147 Human genes 0.000 description 2
- 102220097541 rs201529791 Human genes 0.000 description 2
- 102220154768 rs2073875 Human genes 0.000 description 2
- 102220027209 rs267607813 Human genes 0.000 description 2
- 102220035599 rs276174805 Human genes 0.000 description 2
- 102220214853 rs281860296 Human genes 0.000 description 2
- 102200076374 rs28935195 Human genes 0.000 description 2
- 102200077267 rs28935485 Human genes 0.000 description 2
- 102200077255 rs28935488 Human genes 0.000 description 2
- 102200087966 rs3211299 Human genes 0.000 description 2
- 102200082928 rs33926796 Human genes 0.000 description 2
- 102220005306 rs33926796 Human genes 0.000 description 2
- 102220005246 rs34022507 Human genes 0.000 description 2
- 102220005494 rs34849179 Human genes 0.000 description 2
- 102220005453 rs34890875 Human genes 0.000 description 2
- 102220135947 rs370711366 Human genes 0.000 description 2
- 102220055238 rs372416832 Human genes 0.000 description 2
- 102200076486 rs372966991 Human genes 0.000 description 2
- 102220045748 rs374078532 Human genes 0.000 description 2
- 102220082985 rs375349172 Human genes 0.000 description 2
- 102220214839 rs375401722 Human genes 0.000 description 2
- 102220224944 rs375661583 Human genes 0.000 description 2
- 102220234869 rs376280361 Human genes 0.000 description 2
- 102220093850 rs376561094 Human genes 0.000 description 2
- 102220250258 rs377226281 Human genes 0.000 description 2
- 102200033047 rs387906763 Human genes 0.000 description 2
- 102220410258 rs387907161 Human genes 0.000 description 2
- 102220231583 rs397507822 Human genes 0.000 description 2
- 102220044620 rs397507878 Human genes 0.000 description 2
- 102220020349 rs397508137 Human genes 0.000 description 2
- 102220020844 rs397508812 Human genes 0.000 description 2
- 102220022296 rs397509338 Human genes 0.000 description 2
- 102200076445 rs397515870 Human genes 0.000 description 2
- 102220012154 rs397515871 Human genes 0.000 description 2
- 102220012156 rs397515873 Human genes 0.000 description 2
- 102200076597 rs397515873 Human genes 0.000 description 2
- 102200076869 rs398123201 Human genes 0.000 description 2
- 102220028740 rs398123204 Human genes 0.000 description 2
- 102220028749 rs398123217 Human genes 0.000 description 2
- 102220028757 rs398123223 Human genes 0.000 description 2
- 102220056052 rs398123224 Human genes 0.000 description 2
- 102220028761 rs398123227 Human genes 0.000 description 2
- 102220031191 rs398124359 Human genes 0.000 description 2
- 102220096672 rs45447991 Human genes 0.000 description 2
- 102200057453 rs45494092 Human genes 0.000 description 2
- 102200091192 rs5030820 Human genes 0.000 description 2
- 102220104788 rs546499094 Human genes 0.000 description 2
- 102220036614 rs548898238 Human genes 0.000 description 2
- 102220012750 rs56023295 Human genes 0.000 description 2
- 102220045134 rs56026142 Human genes 0.000 description 2
- 102220036077 rs57605939 Human genes 0.000 description 2
- 102200071160 rs587776955 Human genes 0.000 description 2
- 102220034623 rs587779420 Human genes 0.000 description 2
- 102220034558 rs587779569 Human genes 0.000 description 2
- 102220045083 rs587780062 Human genes 0.000 description 2
- 102220041657 rs587780672 Human genes 0.000 description 2
- 102220058791 rs587781374 Human genes 0.000 description 2
- 102200106406 rs587781589 Human genes 0.000 description 2
- 102200140598 rs587781663 Human genes 0.000 description 2
- 102220276509 rs587781703 Human genes 0.000 description 2
- 102220044978 rs587781728 Human genes 0.000 description 2
- 102220045034 rs587781775 Human genes 0.000 description 2
- 102200102699 rs587781845 Human genes 0.000 description 2
- 102220045151 rs587781864 Human genes 0.000 description 2
- 102220045295 rs587781986 Human genes 0.000 description 2
- 102220045417 rs587782087 Human genes 0.000 description 2
- 102200108958 rs587782197 Human genes 0.000 description 2
- 102220045953 rs587782513 Human genes 0.000 description 2
- 102220046114 rs587782658 Human genes 0.000 description 2
- 102220046246 rs587782764 Human genes 0.000 description 2
- 102220049651 rs59662841 Human genes 0.000 description 2
- 102220024649 rs60290646 Human genes 0.000 description 2
- 102220033195 rs61752907 Human genes 0.000 description 2
- 102200031103 rs62507329 Human genes 0.000 description 2
- 102220027080 rs63750102 Human genes 0.000 description 2
- 102200163551 rs63751012 Human genes 0.000 description 2
- 102200027523 rs63751444 Human genes 0.000 description 2
- 102200101878 rs72556287 Human genes 0.000 description 2
- 102200076419 rs727503950 Human genes 0.000 description 2
- 102220249169 rs727504247 Human genes 0.000 description 2
- 102200077186 rs727504348 Human genes 0.000 description 2
- 102220055970 rs727504372 Human genes 0.000 description 2
- 102220056032 rs727504689 Human genes 0.000 description 2
- 102200077331 rs727505292 Human genes 0.000 description 2
- 102220057309 rs730880441 Human genes 0.000 description 2
- 102220088223 rs730880442 Human genes 0.000 description 2
- 102220057314 rs730880450 Human genes 0.000 description 2
- 102220057176 rs730880834 Human genes 0.000 description 2
- 102220057745 rs730881370 Human genes 0.000 description 2
- 102220057806 rs730881924 Human genes 0.000 description 2
- 102220058235 rs730881926 Human genes 0.000 description 2
- 102220062023 rs730881926 Human genes 0.000 description 2
- 102220277657 rs746045584 Human genes 0.000 description 2
- 102200006407 rs746834149 Human genes 0.000 description 2
- 102220122949 rs747399155 Human genes 0.000 description 2
- 102220236853 rs748675395 Human genes 0.000 description 2
- 102220093316 rs749037674 Human genes 0.000 description 2
- 102220214503 rs749545338 Human genes 0.000 description 2
- 102220105060 rs749645694 Human genes 0.000 description 2
- 102220093690 rs749927908 Human genes 0.000 description 2
- 102220061691 rs750621215 Human genes 0.000 description 2
- 102220311628 rs751425296 Human genes 0.000 description 2
- 102220298573 rs751886390 Human genes 0.000 description 2
- 102220104591 rs756750256 Human genes 0.000 description 2
- 102220124481 rs756780233 Human genes 0.000 description 2
- 102220193153 rs756921902 Human genes 0.000 description 2
- 102220101427 rs759673348 Human genes 0.000 description 2
- 102220234054 rs759799287 Human genes 0.000 description 2
- 102220219019 rs759812068 Human genes 0.000 description 2
- 102200065197 rs760277934 Human genes 0.000 description 2
- 102220242446 rs761384727 Human genes 0.000 description 2
- 102220096671 rs761771287 Human genes 0.000 description 2
- 102220120619 rs762718963 Human genes 0.000 description 2
- 102220219961 rs762772484 Human genes 0.000 description 2
- 102220257452 rs763104308 Human genes 0.000 description 2
- 102220114730 rs763889166 Human genes 0.000 description 2
- 102220278676 rs769967916 Human genes 0.000 description 2
- 102220227683 rs771817870 Human genes 0.000 description 2
- 102220285290 rs772747395 Human genes 0.000 description 2
- 102220103583 rs776369486 Human genes 0.000 description 2
- 102220272713 rs777653224 Human genes 0.000 description 2
- 102220076190 rs777988634 Human genes 0.000 description 2
- 102220213120 rs778385281 Human genes 0.000 description 2
- 102220227707 rs779346343 Human genes 0.000 description 2
- 102220094458 rs779917781 Human genes 0.000 description 2
- 102220248486 rs780197880 Human genes 0.000 description 2
- 102220094252 rs780350978 Human genes 0.000 description 2
- 102200076456 rs781838005 Human genes 0.000 description 2
- 102220105141 rs781871113 Human genes 0.000 description 2
- 102220331395 rs782196174 Human genes 0.000 description 2
- 102220340382 rs782584884 Human genes 0.000 description 2
- 102220087839 rs782722577 Human genes 0.000 description 2
- 102220062314 rs786201228 Human genes 0.000 description 2
- 102220061173 rs786201393 Human genes 0.000 description 2
- 102220060550 rs786201716 Human genes 0.000 description 2
- 102220061688 rs786201961 Human genes 0.000 description 2
- 102200107874 rs786202717 Human genes 0.000 description 2
- 102220062189 rs786203298 Human genes 0.000 description 2
- 102220075293 rs796052413 Human genes 0.000 description 2
- 102220074984 rs796052967 Human genes 0.000 description 2
- 102220070199 rs797044776 Human genes 0.000 description 2
- 102220021041 rs80356864 Human genes 0.000 description 2
- 102220327886 rs80356929 Human genes 0.000 description 2
- 102220022209 rs80357142 Human genes 0.000 description 2
- 102220022305 rs80357252 Human genes 0.000 description 2
- 102220022230 rs80357410 Human genes 0.000 description 2
- 102220021082 rs80357471 Human genes 0.000 description 2
- 102220018750 rs80358450 Human genes 0.000 description 2
- 102220019522 rs80358865 Human genes 0.000 description 2
- 102220087048 rs864622342 Human genes 0.000 description 2
- 102220086687 rs864622764 Human genes 0.000 description 2
- 102220159865 rs865963367 Human genes 0.000 description 2
- 102220088402 rs869025630 Human genes 0.000 description 2
- 102200076842 rs869312134 Human genes 0.000 description 2
- 102200076860 rs869312136 Human genes 0.000 description 2
- 102200076864 rs869312138 Human genes 0.000 description 2
- 102200076412 rs869312146 Human genes 0.000 description 2
- 102200076444 rs869312149 Human genes 0.000 description 2
- 102200076443 rs869312150 Human genes 0.000 description 2
- 102200076561 rs869312152 Human genes 0.000 description 2
- 102200077294 rs869312155 Human genes 0.000 description 2
- 102200077326 rs869312159 Human genes 0.000 description 2
- 102200077330 rs869312160 Human genes 0.000 description 2
- 102200077131 rs869312161 Human genes 0.000 description 2
- 102200077157 rs869312162 Human genes 0.000 description 2
- 102200077153 rs869312163 Human genes 0.000 description 2
- 102200077155 rs869312163 Human genes 0.000 description 2
- 102220087825 rs869312218 Human genes 0.000 description 2
- 102200077332 rs869312399 Human genes 0.000 description 2
- 102220087829 rs869312427 Human genes 0.000 description 2
- 102220090287 rs875989951 Human genes 0.000 description 2
- 102220093882 rs876658745 Human genes 0.000 description 2
- 102220095353 rs876659078 Human genes 0.000 description 2
- 102220096898 rs876660103 Human genes 0.000 description 2
- 102220097208 rs876660256 Human genes 0.000 description 2
- 102220095215 rs876660436 Human genes 0.000 description 2
- 102220096755 rs876660744 Human genes 0.000 description 2
- 102200077205 rs878853698 Human genes 0.000 description 2
- 102220103979 rs878853698 Human genes 0.000 description 2
- 102220099834 rs878853775 Human genes 0.000 description 2
- 102220099062 rs878854195 Human genes 0.000 description 2
- 102220102780 rs878855124 Human genes 0.000 description 2
- 102220105072 rs879254159 Human genes 0.000 description 2
- 102220122925 rs886043260 Human genes 0.000 description 2
- 102220127785 rs886044698 Human genes 0.000 description 2
- 102220125097 rs886044879 Human genes 0.000 description 2
- 102220129544 rs886045584 Human genes 0.000 description 2
- 102220218047 rs922057169 Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 102220486135 Alpha-galactosidase A_C56F_mutation Human genes 0.000 description 1
- 102220486287 Alpha-galactosidase A_G260A_mutation Human genes 0.000 description 1
- 102220505043 Alpha-galactosidase A_G360C_mutation Human genes 0.000 description 1
- 102220486653 Alpha-galactosidase A_I242N_mutation Human genes 0.000 description 1
- 102220486406 Alpha-galactosidase A_M187V_mutation Human genes 0.000 description 1
- 102220486151 Alpha-galactosidase A_M72V_mutation Human genes 0.000 description 1
- 102220480371 Alpha-galactosidase A_P409T_mutation Human genes 0.000 description 1
- 102220486351 Alpha-galactosidase A_Q280H_mutation Human genes 0.000 description 1
- 102220486423 Alpha-galactosidase A_Y216D_mutation Human genes 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241001463143 Auca Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102220493496 EF-hand calcium-binding domain-containing protein 12_E66G_mutation Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000011755 Hearing abnormality Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 241000368538 Hemiancistrus medians Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000003430 Mitral Valve Prolapse Diseases 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102220602509 Small integral membrane protein 1_M51K_mutation Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102220514548 Somatostatin receptor type 1_N34K_mutation Human genes 0.000 description 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960001239 agalsidase alfa Drugs 0.000 description 1
- 108010056760 agalsidase beta Proteins 0.000 description 1
- 229960004470 agalsidase beta Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 201000009431 angiokeratoma Diseases 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000002665 bowman capsule Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 102220360419 c.1073A>G Human genes 0.000 description 1
- 102220364490 c.11G>T Human genes 0.000 description 1
- 102220350714 c.122C>T Human genes 0.000 description 1
- 102220362001 c.164A>G Human genes 0.000 description 1
- 102220432327 c.227T>C Human genes 0.000 description 1
- 102220389247 c.408T>A Human genes 0.000 description 1
- 102220355413 c.437C>G Human genes 0.000 description 1
- 102220354804 c.602C>T Human genes 0.000 description 1
- 102220349963 c.844A>G Human genes 0.000 description 1
- 102220360619 c.919G>A Human genes 0.000 description 1
- 102220347057 c.938A>G Human genes 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000004303 calcium sorbate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- KUBARPMUNHKBIQ-VTHUDJRQSA-N eliglustat tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 KUBARPMUNHKBIQ-VTHUDJRQSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000005086 glomerual capillary Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 150000002305 glucosylceramides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000010039 intracellular degradation Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000000210 loop of henle Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 208000005907 mitral valve insufficiency Diseases 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102200006404 rs104894109 Human genes 0.000 description 1
- 102200108726 rs104894494 Human genes 0.000 description 1
- 102200046996 rs104894932 Human genes 0.000 description 1
- 102220258042 rs104894997 Human genes 0.000 description 1
- 102220199425 rs1057521425 Human genes 0.000 description 1
- 102220210542 rs1057524799 Human genes 0.000 description 1
- 102220231152 rs1064796391 Human genes 0.000 description 1
- 102220059766 rs116481522 Human genes 0.000 description 1
- 102220287368 rs1190318676 Human genes 0.000 description 1
- 102220001684 rs121908149 Human genes 0.000 description 1
- 102200140254 rs121913317 Human genes 0.000 description 1
- 102200126968 rs121918499 Human genes 0.000 description 1
- 102220004430 rs121918700 Human genes 0.000 description 1
- 102220268908 rs1273577069 Human genes 0.000 description 1
- 102220251787 rs1322163466 Human genes 0.000 description 1
- 102200046718 rs1365923535 Human genes 0.000 description 1
- 102220303180 rs1400601775 Human genes 0.000 description 1
- 102220104213 rs140506267 Human genes 0.000 description 1
- 102220012147 rs144994244 Human genes 0.000 description 1
- 102220289671 rs147977741 Human genes 0.000 description 1
- 102220247478 rs148833310 Human genes 0.000 description 1
- 102220280102 rs1555012795 Human genes 0.000 description 1
- 102220282652 rs1555603052 Human genes 0.000 description 1
- 102220273265 rs1555615732 Human genes 0.000 description 1
- 102220328979 rs1555685152 Human genes 0.000 description 1
- 102220253014 rs1555975685 Human genes 0.000 description 1
- 102220009109 rs193922344 Human genes 0.000 description 1
- 102220228444 rs200183599 Human genes 0.000 description 1
- 102200077328 rs28935492 Human genes 0.000 description 1
- 102220203646 rs371529625 Human genes 0.000 description 1
- 102220062541 rs372189599 Human genes 0.000 description 1
- 102220214294 rs373488862 Human genes 0.000 description 1
- 102220096855 rs386833401 Human genes 0.000 description 1
- 102200033267 rs387906767 Human genes 0.000 description 1
- 102200154673 rs387907183 Human genes 0.000 description 1
- 102220020237 rs397508065 Human genes 0.000 description 1
- 102220012148 rs397515869 Human genes 0.000 description 1
- 102200105993 rs397516435 Human genes 0.000 description 1
- 102220208140 rs550757849 Human genes 0.000 description 1
- 102220106470 rs569543350 Human genes 0.000 description 1
- 102220041299 rs587778715 Human genes 0.000 description 1
- 102220037633 rs587780322 Human genes 0.000 description 1
- 102220229612 rs587780824 Human genes 0.000 description 1
- 102220098970 rs61750991 Human genes 0.000 description 1
- 102220053622 rs727502878 Human genes 0.000 description 1
- 102220053780 rs727505148 Human genes 0.000 description 1
- 102220217847 rs746677418 Human genes 0.000 description 1
- 102200006408 rs746834149 Human genes 0.000 description 1
- 102220217844 rs747356389 Human genes 0.000 description 1
- 102220082173 rs74755920 Human genes 0.000 description 1
- 102220098947 rs749510661 Human genes 0.000 description 1
- 102220324857 rs754678843 Human genes 0.000 description 1
- 102220226535 rs754898711 Human genes 0.000 description 1
- 102200068463 rs760106433 Human genes 0.000 description 1
- 102220313667 rs761873230 Human genes 0.000 description 1
- 102220334495 rs766896575 Human genes 0.000 description 1
- 102220282696 rs775224480 Human genes 0.000 description 1
- 102220064361 rs786205803 Human genes 0.000 description 1
- 102220072165 rs794728673 Human genes 0.000 description 1
- 102220075588 rs796053298 Human genes 0.000 description 1
- 102220077787 rs797045071 Human genes 0.000 description 1
- 102200145266 rs80338946 Human genes 0.000 description 1
- 102220081428 rs863223820 Human genes 0.000 description 1
- 102220283610 rs863224500 Human genes 0.000 description 1
- 102200076414 rs869312145 Human genes 0.000 description 1
- 102220087831 rs869312396 Human genes 0.000 description 1
- 102200160956 rs869320708 Human genes 0.000 description 1
- 102220095165 rs876660152 Human genes 0.000 description 1
- 102220094402 rs876660301 Human genes 0.000 description 1
- 102200006426 rs878853650 Human genes 0.000 description 1
- 102200105318 rs886039484 Human genes 0.000 description 1
- 102220121662 rs886042900 Human genes 0.000 description 1
- 102220191009 rs886056546 Human genes 0.000 description 1
- 102220288404 rs920394412 Human genes 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762512458P | 2017-05-30 | 2017-05-30 | |
| US62/512,458 | 2017-05-30 | ||
| US201862626953P | 2018-02-06 | 2018-02-06 | |
| US62/626,953 | 2018-02-06 | ||
| US15/992,336 US10251873B2 (en) | 2017-05-30 | 2018-05-30 | Methods of treating fabry patients having renal impairment |
| CA3065298A CA3065298A1 (fr) | 2017-05-30 | 2018-05-30 | Methodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance renale |
| US15/992,336 | 2018-05-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3065298A Division CA3065298A1 (fr) | 2017-05-30 | 2018-05-30 | Methodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance renale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3224546A1 true CA3224546A1 (fr) | 2018-12-06 |
Family
ID=62705693
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3065298A Pending CA3065298A1 (fr) | 2017-05-30 | 2018-05-30 | Methodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance renale |
| CA3224537A Pending CA3224537A1 (fr) | 2017-05-30 | 2018-05-30 | Utilisation du migalastat dans le traitement des patients atteints de lamaladie de fabry presentant une deficience renale |
| CA3224546A Pending CA3224546A1 (fr) | 2017-05-30 | 2018-05-30 | Utilisation du migalastat dans le traitement des patients atteints de lamaladie de fabry presentant une deficience renale |
| CA3224529A Pending CA3224529A1 (fr) | 2017-05-30 | 2018-05-30 | Methodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance renale |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3065298A Pending CA3065298A1 (fr) | 2017-05-30 | 2018-05-30 | Methodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance renale |
| CA3224537A Pending CA3224537A1 (fr) | 2017-05-30 | 2018-05-30 | Utilisation du migalastat dans le traitement des patients atteints de lamaladie de fabry presentant une deficience renale |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3224529A Pending CA3224529A1 (fr) | 2017-05-30 | 2018-05-30 | Methodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance renale |
Country Status (11)
| Country | Link |
|---|---|
| US (45) | US10251873B2 (fr) |
| JP (6) | JP2020507562A (fr) |
| KR (6) | KR20240017112A (fr) |
| AU (1) | AU2018277756A1 (fr) |
| BR (1) | BR112019025083B1 (fr) |
| CA (4) | CA3065298A1 (fr) |
| CL (1) | CL2019003496A1 (fr) |
| CO (1) | CO2019015026A2 (fr) |
| IL (1) | IL270956A (fr) |
| MX (2) | MX2019014410A (fr) |
| WO (1) | WO2018222655A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3457135A1 (fr) | 2006-05-16 | 2019-03-20 | Amicus Therapeutics, Inc. | Options de traitement pour la maladie de fabry |
| PL3470077T3 (pl) | 2008-02-12 | 2021-04-06 | Amicus Therapeutics, Inc. | Sposób przewidywania odpowiedzi na leczenie chorób chaperonami farmakologicznymi |
| CN114159436A (zh) * | 2016-03-22 | 2022-03-11 | 阿米库斯治疗学公司 | 治疗在gla基因中具有g9331a突变的患者的法布里病的方法 |
| KR20240017112A (ko) | 2017-05-30 | 2024-02-06 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 신장 손상을 갖는 파브리 환자를 치료하는 방법 |
| EP3749307A1 (fr) | 2018-02-06 | 2020-12-16 | Amicus Therapeutics, Inc. | Utilisation de migalastat pour le traitement de la maladie de fabry chez des patientes enceintes |
| CA3110065A1 (fr) * | 2018-08-20 | 2020-02-27 | Amicus Therapeutics, Inc. | Methodes de traitement de la maladie de fabry chez les patients porteurs d'une mutation du gene gla |
| WO2020252129A1 (fr) * | 2019-06-11 | 2020-12-17 | Amicus Therapeutics, Inc. | Méthodes de traitement de la maladie de fabry chez des patients ayant une déficience rénale |
| CA3147055A1 (fr) | 2019-08-07 | 2021-02-11 | Elfrida Benjamin | Methodes de traitement de la maladie de fabry chez les patients porteurs d'une mutation du gene gla |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
| USD961304S1 (en) * | 2021-05-25 | 2022-08-23 | Paolo Castelli | Furniture for bathrooms |
| USD960619S1 (en) * | 2021-05-26 | 2022-08-16 | Paolo Castelli | Furniture for bathrooms |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| WO2008045015A1 (fr) | 2005-06-08 | 2008-04-17 | Amicus Therapeutics, Inc. | Purification d'imino- et amino-sucre |
| EP3457135A1 (fr) | 2006-05-16 | 2019-03-20 | Amicus Therapeutics, Inc. | Options de traitement pour la maladie de fabry |
| MX2009010557A (es) | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. |
| US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| WO2008134628A2 (fr) | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Schémas posologiques pour le traitement de maladies de stockage lysosomal en utilisant des chaperons pharmacologiques |
| PL3470077T3 (pl) | 2008-02-12 | 2021-04-06 | Amicus Therapeutics, Inc. | Sposób przewidywania odpowiedzi na leczenie chorób chaperonami farmakologicznymi |
| US8321148B2 (en) | 2008-10-24 | 2012-11-27 | Amicus Therapeutics, Inc. | Multiple compartment dosing model |
| US9206457B2 (en) | 2009-05-26 | 2015-12-08 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
| US20110070643A1 (en) | 2009-05-26 | 2011-03-24 | Do Hung V | Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics |
| US20120154681A1 (en) * | 2009-07-17 | 2012-06-21 | Takeshi Morimoto | Diaphragm control circuit, projector device, diaphragm control program and diaphragm control method |
| JP5739898B2 (ja) | 2009-11-17 | 2015-06-24 | ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 心疾患マーカーとしての尿中トリアオシルセラミド（ｇｂ３） |
| CN103974619B (zh) | 2011-03-11 | 2017-02-15 | 阿米库斯治疗学公司 | 治疗法布里病的给药方案 |
| US20120283290A1 (en) | 2011-05-06 | 2012-11-08 | Amicus Therapeutics Inc. | Quantitation of gl3 in urine |
| JP6320931B2 (ja) | 2011-12-22 | 2018-05-09 | セントジーン アイピー ゲーエムベーハー | リソソーム酵素を再構成する能力を有する化合物ならびにアンブロキソールおよび／またはアンブロキソールの誘導体の組み合わせ |
| US10155027B2 (en) | 2012-07-17 | 2018-12-18 | Amicus Therapeutics, Inc. | Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease |
| EP2874648A4 (fr) | 2012-07-17 | 2015-12-30 | Amicus Therapeutics Inc | Co-formulation d'alpha-galactosidase a et de 1-désoxygalactonojirimycine |
| US20170051267A1 (en) | 2015-08-20 | 2017-02-23 | Research Foundation Of The City University Of New York | Novel alpha-galactosidase a derivatives |
| CN114159436A (zh) | 2016-03-22 | 2022-03-11 | 阿米库斯治疗学公司 | 治疗在gla基因中具有g9331a突变的患者的法布里病的方法 |
| US20190183869A1 (en) | 2016-07-19 | 2019-06-20 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naïve and ert-experienced patients |
| JP2020503900A (ja) | 2017-01-10 | 2020-02-06 | アミカス セラピューティックス インコーポレイテッド | ファブリー病の処置のための組換えアルファ−ガラクトシダーゼａ |
| KR20240017112A (ko) | 2017-05-30 | 2024-02-06 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 신장 손상을 갖는 파브리 환자를 치료하는 방법 |
| SG11202000423XA (en) | 2017-07-19 | 2020-02-27 | Amicus Therapeutics Inc | Treatment of fabry disease in ert-naïve and ert-experienced patients |
| EP4176877A1 (fr) | 2017-08-28 | 2023-05-10 | Amicus Therapeutics, Inc. | Procédés pour améliorer et/ou stabiliser la fonction cardiaque chez des patients atteints de la maladie de fabry |
| US20210038579A1 (en) | 2018-02-06 | 2021-02-11 | Amicus Therapeutics, Inc. | Treatment Of Patients With Classic Fabry Disease |
| EP3749307A1 (fr) | 2018-02-06 | 2020-12-16 | Amicus Therapeutics, Inc. | Utilisation de migalastat pour le traitement de la maladie de fabry chez des patientes enceintes |
| CA3110065A1 (fr) | 2018-08-20 | 2020-02-27 | Amicus Therapeutics, Inc. | Methodes de traitement de la maladie de fabry chez les patients porteurs d'une mutation du gene gla |
| WO2020252129A1 (fr) | 2019-06-11 | 2020-12-17 | Amicus Therapeutics, Inc. | Méthodes de traitement de la maladie de fabry chez des patients ayant une déficience rénale |
| CA3147055A1 (fr) | 2019-08-07 | 2021-02-11 | Elfrida Benjamin | Methodes de traitement de la maladie de fabry chez les patients porteurs d'une mutation du gene gla |
| US20210251972A1 (en) | 2020-02-10 | 2021-08-19 | Amicus Therapeutics, Inc. | Methods Of Treating Fabry Disease |
-
2018
- 2018-05-30 KR KR1020247003115A patent/KR20240017112A/ko active Search and Examination
- 2018-05-30 AU AU2018277756A patent/AU2018277756A1/en active Pending
- 2018-05-30 MX MX2019014410A patent/MX2019014410A/es unknown
- 2018-05-30 CA CA3065298A patent/CA3065298A1/fr active Pending
- 2018-05-30 CA CA3224537A patent/CA3224537A1/fr active Pending
- 2018-05-30 CA CA3224546A patent/CA3224546A1/fr active Pending
- 2018-05-30 KR KR1020217016473A patent/KR102427610B1/ko active IP Right Grant
- 2018-05-30 KR KR1020227025898A patent/KR20220116305A/ko not_active Application Discontinuation
- 2018-05-30 US US15/992,336 patent/US10251873B2/en active Active
- 2018-05-30 JP JP2019539797A patent/JP2020507562A/ja active Pending
- 2018-05-30 BR BR112019025083-2A patent/BR112019025083B1/pt active IP Right Grant
- 2018-05-30 KR KR1020197038266A patent/KR102631805B1/ko active IP Right Grant
- 2018-05-30 KR KR1020247003113A patent/KR20240017110A/ko active Search and Examination
- 2018-05-30 KR KR1020247003114A patent/KR20240017111A/ko active Search and Examination
- 2018-05-30 WO PCT/US2018/035032 patent/WO2018222655A1/fr active Application Filing
- 2018-05-30 CA CA3224529A patent/CA3224529A1/fr active Pending
-
2019
- 2019-02-25 US US16/284,582 patent/US10471053B2/en active Active
- 2019-11-08 US US16/678,183 patent/US10874655B2/en active Active
- 2019-11-26 IL IL270956A patent/IL270956A/en unknown
- 2019-11-29 CL CL2019003496A patent/CL2019003496A1/es unknown
- 2019-11-29 MX MX2022004137A patent/MX2022004137A/es unknown
- 2019-12-19 JP JP2019229050A patent/JP6788725B2/ja active Active
- 2019-12-30 CO CONC2019/0015026A patent/CO2019015026A2/es unknown
-
2020
- 2020-03-13 US US16/817,918 patent/US10806727B2/en active Active
- 2020-03-13 US US16/817,908 patent/US10799491B2/en active Active
- 2020-03-13 US US16/817,895 patent/US10874657B2/en active Active
- 2020-03-13 US US16/817,925 patent/US10849890B2/en active Active
- 2020-03-13 US US16/817,927 patent/US10792279B2/en active Active
- 2020-03-13 US US16/817,877 patent/US10849889B2/en active Active
- 2020-03-13 US US16/817,881 patent/US10857141B2/en active Active
- 2020-03-13 US US16/817,888 patent/US10874656B2/en active Active
- 2020-03-13 US US16/817,900 patent/US10857142B2/en active Active
- 2020-03-13 US US16/817,911 patent/US10792278B2/en active Active
- 2020-07-20 JP JP2020123392A patent/JP2020203886A/ja active Pending
- 2020-10-21 US US17/076,340 patent/US11612593B2/en active Active
- 2020-10-21 US US17/076,336 patent/US11633387B2/en active Active
- 2020-10-22 US US17/077,397 patent/US11642334B2/en active Active
- 2020-10-22 US US17/077,389 patent/US11612594B2/en active Active
- 2020-10-22 US US17/077,393 patent/US11826360B2/en active Active
- 2020-10-22 US US17/077,402 patent/US11622962B2/en active Active
- 2020-10-23 US US17/078,840 patent/US20210038583A1/en active Pending
- 2020-10-23 US US17/078,765 patent/US11633388B2/en active Active
-
2021
- 2021-03-26 US US17/213,632 patent/US11903938B2/en active Active
- 2021-08-04 US US17/393,971 patent/US11304940B2/en active Active
- 2021-08-12 US US17/400,626 patent/US11278537B2/en active Active
- 2021-08-12 US US17/400,548 patent/US11357761B2/en active Active
- 2021-08-12 US US17/400,932 patent/US11357763B2/en active Active
- 2021-08-12 US US17/400,614 patent/US11357762B2/en active Active
- 2021-08-12 US US17/400,927 patent/US11278539B2/en active Active
- 2021-08-12 US US17/400,623 patent/US11278536B2/en active Active
- 2021-08-12 US US17/400,922 patent/US11278538B2/en active Active
- 2021-08-13 US US17/401,629 patent/US11278540B2/en active Active
-
2022
- 2022-02-11 US US17/670,095 patent/US11376244B2/en active Active
- 2022-02-11 US US17/670,083 patent/US11357764B1/en active Active
- 2022-02-11 US US17/670,076 patent/US11426396B2/en active Active
- 2022-02-11 US US17/670,088 patent/US11357765B1/en active Active
- 2022-02-18 US US17/675,587 patent/US11389437B2/en active Active
- 2022-02-18 US US17/675,532 patent/US11389436B2/en active Active
- 2022-02-18 US US17/675,536 patent/US11666564B2/en active Active
- 2022-02-18 US US17/675,544 patent/US11458128B2/en active Active
- 2022-03-02 JP JP2022031518A patent/JP2022071094A/ja not_active Withdrawn
- 2022-12-21 US US18/069,720 patent/US11786516B2/en active Active
- 2022-12-21 JP JP2022204185A patent/JP2023052005A/ja active Pending
- 2022-12-21 US US18/069,716 patent/US11813255B2/en active Active
- 2022-12-21 US US18/069,732 patent/US20230218599A1/en active Pending
-
2023
- 2023-04-13 JP JP2023065461A patent/JP2023100658A/ja active Pending
- 2023-05-31 US US18/326,281 patent/US20230381165A1/en active Pending
- 2023-05-31 US US18/326,279 patent/US20240122911A1/en active Pending
- 2023-05-31 US US18/326,274 patent/US20230381164A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11357761B2 (en) | Methods of treating Fabry patients having renal impairment | |
| EP4374918A2 (fr) | Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231222 |
|
| EEER | Examination request |
Effective date: 20231222 |
|
| EEER | Examination request |
Effective date: 20231222 |
|
| EEER | Examination request |
Effective date: 20231222 |
|
| EEER | Examination request |
Effective date: 20231222 |
|
| EEER | Examination request |
Effective date: 20231222 |